Ratings (MIS) revenue is bond-issuance-cyclical — a credit-market freeze compresses the highest-margin segment fast
One-line thesis. Moody's is one of the highest-quality franchises in the S&P 500 — a ratings duopoly with 67% MIS margins plus a growing subscription-analytics annuity (MA ARR +8%) — but at 35× trailing on ~11% forward EPS growth the stock is priced for perfection while the shares have gone nowhere for a year (−2% vs SPY +21%). Wonderful business, unexciting entry: Watch.
◆ Synthos call — HoldMCO is a solid business largely reflected at ~$500 — fine to keep, no reason to chase; it gets interesting again below ~$425.
Downside Risk (lower = safer)
6/10 · High
Fortress duopoly economics & 1.5× net-debt/EBITDA, but 35× trailing on ~11% EPS growth and MIS revenue is issuance-cyclical.
Growth Quality
7/10 · High
~11% forward EPS CAGR, 70% gross margin, 67% ROE, recurring MA ARR +8% — high quality, moderate pace.
Exponential Potential
3/10 · Low
Great franchise but decelerating and mid-cap-mature; $86B cap on a slow-TAM annuity caps the multibagger.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 18%/yrTo justify today’s $491, earnings would have to compound roughly 18% a year for 10 years (9% discount rate). Analysts forecast ~13%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Moody's is one of the two big companies (the other is S&P Global) that grade how risky a bond is. When a government or company borrows money by issuing a bond, they pay Moody's to stamp it with a rating like "AAA" or "BBB." Almost every big bond in the world needs one of these stamps, and there are only two firms that matter — so it's a toll booth on global borrowing. Moody's also sells subscriptions to risk data and software (the "Analytics" side), which brings in steady, repeat revenue.
The catch: this is a great business at an expensive price. You're paying about $35 for every $1 the company earns, which is steep for a company whose profit is growing around 11% a year. And the stock has actually gone nowhere for the past year while the overall market rose about 21%. Our verdict is Watch — admire it, put it on your list, but there's no rush to buy at today's price. Wait for a dip.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The company itself is rock-solid, but the stock is priced high, and half its business rises and falls with how many bonds get issued — which can dry up in a scare.
Growth Quality 7/10 (good). A genuinely excellent, highly profitable business growing at a steady, healthy clip — just not a rocket.
Exponential Potential 3/10 (low). It's already big and mature; expect steady singles and doubles over years, not a fast multiplier.
The one big worry: roughly half of Moody's profit comes from rating new bonds. When interest rates spike or markets panic, companies stop issuing bonds, and that high-margin revenue can fall sharply — as it did in 2022.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = MCO · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$490.51
Market cap$86B
P/E trailing21×
P/E FY26E / FY27E29× / 26×
EV / Sales11.6×
EV / EBITDA23.2×
Gross margin69.7%
Net margin31.7%
Dividend yield0.80%
Beta1.335
52-wk range$412 – $540
RSI(14)70
50 / 200-DMA$452 / $471
12-mo return+-2% (SPY +21%)
Street target$541 ($489–$610)
Analyst grades18 Buy · 13 Hold · 1 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MCO · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Moody's Corporation (NYSE: MCO) is a ~125-year-old global risk-assessment company that runs on two engines. Fiscal year ends December 31.
Moody's Investors Service (MIS) — the credit-ratings agency. It rates corporate, financial, sovereign, public-finance, and structured-finance debt across ~140 countries. This is the crown jewel: a ratings duopoly with S&P Global, ~67% adjusted operating margin (Q1'26), and revenue that scales with bond-issuance volume. Largely transactional (issuers pay per rating), so it is issuance-cyclical.
Moody's Analytics (MA) — subscription research, data, credit-scoring, economic forecasting, KYC/anti-money-laundering, and risk software. This is the recurring annuity: ~98% recurring revenue, ARR $3.6B growing 8% YoY (Q1'26), ~32.5% adjusted operating margin and expanding.
Segment revenue (FY2025, from filings — labels reconciled to the Q1'26 release): MIS ≈ $4.84B · MA ≈ $2.88B (total $7.72B). (Note: the raw FMP seg_prod feed swaps the two segment labels — the Q1'26 earnings release confirms MIS revenue $1,153M > MA $926M per quarter, so MIS is the larger segment. We use the release as authoritative.)
Geographic mix (FY2025, filings): US is the majority of revenue with International Regions ~$3.55B (EMEA $2.38B, Asia-Pacific $0.70B) — a globally diversified but developed-market-weighted base.
The strategic story management keeps pressing is AI-as-tailwind: MIS benefits from AI/data-center-driven debt financing (hyperscaler bond issuance), and MA sells "decision-grade connected intelligence" into AI workflows (CEO Fauber's Q1'26 framing).
2. The expert thesis
There is no expert coverage of MCO in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0. No independent voice we track — bullish or bearish — has made a traceable, dated claim on Moody's.
Per house standard we say this plainly: this verdict is fundamentals- and quant-driven, not conviction-driven. Nothing below cites a claim_id, because there are none to cite. Readers should weight this note as a data-grounded quant read, not as a call backed by an expert panel. (For context outside our KB, the sell-side is constructive: 18 Buy / 13 Hold / 1 Sell, consensus "Buy" — but sell-side ratings are not part of Synthos conviction and are shown only as external context.)
3. Synthos scores & the Bull / Base / Bear cases
Three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Net-debt/EBITDA 1.5× and 70% gross margin are sturdy, but 35× trailing on ~11% EPS growth (PEG ~1.7–3.0) leaves no cushion, beta is 1.34, and MIS revenue is issuance-cyclical (2022 saw ratings revenue fall).
Growth Quality
7 · High
~11% forward EPS CAGR, 70% gross margin, 67% ROE / 23% ROIC, MA ARR +8% recurring — a top-decile-quality franchise growing at a moderate, durable pace.
Exponential Potential
3 · Low
Forward growth is only ~11% and decelerating; an $86B-cap mature annuity on a slow-growing TAM. Wonderful, but structurally not a multibagger from here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Estimates roughly hit — FY26E EPS $16.71, FY27E $18.65; a durable ~11% compounder earns a ~27× forward multiple. ~27× × $18.65 ≈ $500.
~$500 (+2%)
Bear
Issuance cycle rolls over (rate shock / credit freeze), MIS transactional revenue contracts, multiple de-rates to ~21× on ~$18 FY27 EPS.
~$385 (−22%)
Synthos fair value = the base case, ~$500 (+2%), with the full $385–$610 span as the honest range. Our base sits below the Street's $541 consensus — we are less willing to pay up for ~11% growth at 35× trailing, and we weight the issuance-cyclicality risk more heavily. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MCO is a high-quality compounder with low exponential potential:
Forward growth: revenue CAGR FY25→FY30E ~6.3% ($7.7B → $10.5B); EPS CAGR ~10.6% ($14.72 → $24.39 consensus) as buybacks and margin add to the top line. Solid, not explosive.
Acceleration (the 2nd derivative) is flat-to-negative: EPS growth steps ~13% (FY26E) → ~12% (FY27E) → ~11% (FY28E) → ~9% (FY29E) → ~8% (FY30E). This is a decelerating mature compounder, the opposite of an accelerating exponential. Per our flagship philosophy we hunt forward next-exponentials; MCO is firmly a trailing-compounder profile.
Room to run: the TAM (global debt issuance + risk-analytics subscriptions) is large but grows slowly (GDP-plus), and at $86B market cap Moody's already commands its category. A 5× from here implies a ~$430B firm on a mid-single-digit-revenue-growth annuity — not credible on this decade's math.
Reinvestment runway: capital-light (capex ~1.2% of revenue), so nearly all cash converts to FCF and returns to shareholders via buybacks/dividends — excellent for a compounder, but it means growth comes from price/volume and M&A, not a reinvestment flywheel.
Exponential Potential: Low (3/10). Own MCO (if at all) for durable ~10% earnings compounding plus buybacks, not for a fast multibagger. This is a quality-sleeve name, not a degen-tier bet.
Margins: gross 69.7% TTM, EBIT ~44%, EBITDA ~50%, net 31.7% TTM. Company-reported adjusted operating margin was 53.2% in Q1'26 (MIS 66.7%, MA 32.5%). Elite for any sector.
Returns on capital:ROE 66.7%, ROIC 23.1%, return on tangible assets ~38% — the hallmark of a capital-light franchise (note: high ROE is flattered by a small, buyback-shrunk equity base).
Earnings: net income $2.46B FY25 (EPS diluted $13.67) vs $2.06B / $11.26 FY24. Q1'26 net income $661M, GAAP diluted EPS $3.73 (adjusted $4.33).
Cash flow: operating CF $2.90B FY25, capex just −$326M → FCF $2.58B (FCF margin ~33%). Q1'26 FCF $844M, +26% YoY. Cash-generation is a standout.
Balance sheet: total debt $7.35B, net debt ~$4.97B, net-debt/EBITDA ~1.5× — investment-grade, easily serviceable (interest coverage ~17×). Note tangible book is negative (goodwill/intangibles $8.2B from acquisitions), typical for an asset-light serial acquirer.
6. Valuation — priced in or room?
MCO is not cheap on any trailing metric: 35× EPS, 11.6× sales, 23× EV/EBITDA, 29× P/FCF. The bull's defense is the forward glide-path — on live consensus the P/E compresses to 29× (FY26E) → 26× (FY27E) → ~20× (FY30E)if estimates hit. But that glide is gentler than a fast grower's because EPS only compounds ~11%: trailing PEG is ~1.7 and the forward PEG the FMP feed shows is ~3.0 — i.e. you are paying a premium multiple for moderate growth. A quality franchise deserves a premium, but 35× trailing on ~11% growth prices in continued flawless execution and a supportive issuance cycle. Street targets (context): consensus $541, high $610, low $489 — our ~$500 base FV is below consensus because we discount the multiple for cyclicality and the modest growth rate. Not a value entry; a great-business-at-a-full-price name where the price already reflects the quality.
7. Technicals (from the tech block)
Trend:modestly up. $490.51 sits above the 50-DMA ($452) and 200-DMA ($471) — a constructive posture, but the price only recently reclaimed the 200-DMA.
Location:−9.1% off the 52-week high ($539.61) and +19% off the low ($412.23). Max drawdown from peak ~−9%.
Momentum: RSI(14) 70.4 — right at overbought. MACD +4.5 (positive). The stock popped ~+4.7% on the print-day in the data; entering here means chasing a short-term overbought reading.
Relative strength (the tell): MCO −2.4% over 12 months vs SPY +20.6% and QQQ +30.3% — a material laggard. It has beaten SPY over 3 months (+11.8% vs +13.7%... roughly in line) but the 6- and 12-month relative picture is poor. This is a quality name that the market has left behind for a year.
Read: technicals are mixed and argue against urgency. A near-overbought RSI plus a year of underperformance is a "wait for a pullback toward the rising 50-DMA (~$452) or a cooler RSI" setup, consistent with the Watch verdict.
8. Moat & competitive position
Moody's moat is among the widest in the market: (1) a regulatory-blessed ratings duopoly with S&P Global — issuers effectively must obtain ratings from the two dominant NRSROs to access deep capital markets, a barrier reinforced by a century of brand and regulatory recognition; (2) pricing power — 67% MIS adjusted margins reflect a near-monopoly toll on debt issuance; (3) a sticky subscription annuity in MA (98% recurring, high switching costs in risk/KYC workflows). The durable threats are cyclicality (issuance volume, not moat, drives MIS in any given year), regulatory/liability overhang (post-2008 scrutiny of ratings agencies recurs), and slow disruption risk to MA from broader data/AI competitors.
Peer set (market cap, from feed): the closest true comps are not in the supplied list — MCO's real peer is S&P Global (SPGI) and, in analytics, MSCI ($43.9B) and ICE ($75.2B). Also shown: CME Group ($85.7B), Marsh & McLennan ($89.8B), Brookfield AM ($73.2B), Bank of Montreal, Bank of Nova Scotia, Mizuho, Nu Holdings, Coinbase. Against the exchange/data cohort (CME, ICE, MSCI), MCO commands a premium multiple justified by its duopoly margins — but it is not the fastest grower in that group.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return machine. FY25 returned ~$1.7B in buybacks + $701M dividends; Q1'26 alone returned ~$1.7B (repurchases + dividend), and management raised FY26 buyback guidance to ~$2.5B. Dividend $1.03/qtr ($4.12 annualized, ~0.8% yield), payout ~28% — plenty of coverage. Capex is minimal; this is a return-of-capital story on top of organic growth.
Insider activity: the latest Form 4 cluster (2026-07-01) is CEO Rob Fauber and the General Counsel exercising options and selling into the exercise (S-Sale at $455.49) — routine 10b5-1-style option-exercise-and-sell, plus routine director stock awards. A new CFO/segment leader (Christina Kosmowski named CEO of Moody's Analytics, effective June 2026; Form 3 filed) is a normal succession item, not a red flag.
Management's own guidance (half-weighted — their own book): from the SEC 8-K (Q1'26 earnings release, dated 2026-04-22), management reaffirmed FY2026 guidance: MCO revenue growth in the high-single-digit percent range; operating margin ~45%; adjusted operating margin 52–53%; GAAP diluted EPS $16.00–$16.60 (raised from $15.00–$15.60); adjusted diluted EPS $16.40–$17.00; operating cash flow $3.25–$3.45B; free cash flow $2.8–$3.0B; share repurchases ~$2.5B. Treat as management's self-interested framing — but note the GAAP EPS guide was raised this quarter, a real positive tell. Our base case ($16.71 FY26E consensus) sits within the adjusted-EPS guide.
10. Catalysts & what to watch
Next earnings: 2026-07-22 (Q2'26; Street EPS $4.19, revenue ~$2.07B). Key lines: MIS issuance/transactional revenue (the cyclical swing) and MA ARR growth (is the annuity re-accelerating?).
Bond-issuance environment: rates, credit spreads, and the AI/data-center financing wave — the single biggest driver of MIS in any quarter.
MA ARR trajectory: sustained +8–10% ARR with margin expansion is the quality-durability tell; a slip toward mid-single digits would pressure the multiple.
Buyback execution: ~$2.5B FY26 guide — pace and price of repurchases.
Regulatory: any renewed scrutiny of ratings-agency liability or structure.
Thesis tripwires (what would change the call): two consecutive quarters of MIS transactional-revenue contraction (issuance rollover); MA ARR growth falling below ~6%; adjusted operating margin compressing below ~50%; or a multiple re-rating above ~40× that would flip the verdict toward Avoid on valuation.
11. Key risks
Issuance cyclicality (structural): ~half of profit is MIS transactional, which rises and falls with bond-issuance volume. A rate shock or credit freeze (as in 2022) compresses the highest-margin segment quickly.
Valuation / de-rating: 35× trailing on ~11% growth leaves no margin for error; a growth or issuance disappointment de-rates the stock hard.
Relative-performance drag: the stock has already lagged SPY by ~23 points over 12 months — the market is not currently rewarding the quality, and there's no catalyst forcing a re-rate.
Regulatory/liability overhang: ratings agencies carry recurring political and legal scrutiny risk.
AI as double-edged: management frames AI as a tailwind (financing demand + analytics), but AI could also commoditize parts of the MA data/research annuity over time.
No expert coverage: Synthos has zero traceable KB conviction on this name — the call rests entirely on quant/fundamental analysis, a lower-confidence basis than our conviction-track names.
12. Verdict, position sizing & monitoring
Watch. Moody's is a genuinely elite franchise — a regulatory-moated ratings duopoly (67% MIS margins) bolted to a growing, sticky analytics annuity (MA ARR +8%), throwing off $2.6B of FCF at a ~33% margin with 67% ROE. But three things hold it back from a Buy today: (1) the price — 35× trailing / 29× forward on ~11% EPS growth prices in the quality with no margin of safety; (2) the base-case fair value (~$500) offers only ~+2% to the current $490 and sits below the Street's $541; (3) the tape — the stock is near-overbought (RSI 70) yet has lagged the S&P by ~23 points over a year, so there is neither valuation support nor momentum support to force an entry. Admire it, list it, wait for a pullback.
Sizing: no urgency to initiate. If already owned as a quality compounder, ~2–3% is reasonable; new money should wait for a better entry (toward the rising 50-DMA ~$452 or a sub-$450 print, where the forward multiple and risk/reward improve).
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $490.51.
Single biggest risk: MIS issuance cyclicality — a credit-market freeze compresses the highest-margin revenue fast, and at 35× the stock has no cushion for it.
Provenance & disclosures
Traceability: 0 KB claims, breadth 0 — no expert coverage; this note is explicitly quant/fundamental, with zero fabricated conviction (claim-ID reconciliation makes fabrication structurally impossible — there are simply no claims to cite).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K dated 2026-04-22. Forward figures are analyst consensus (FMP) or company guidance, each labeled as estimates.
Data caveat: the raw FMP seg_prod feed swaps the MIS/MA segment labels; we reconciled to the Q1'26 earnings release (MIS is the larger, higher-margin segment). Sell-side ratings (18 Buy / 13 Hold / 1 Sell) are shown as external context only and are not Synthos conviction.
Management caveat: MCO management guidance is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").